Brief: Nih Advances Activ-5/Bet-B Trial Evaluating Lenzilumab From A Phase 2 Exploratory Study To A Phase 2/3 Study For The Treatment Of Covid-19

Humanigen

30/07/2021 18:00

July 30 (Reuters) - Humanigen Inc  HGEN.O :
    * NIH ADVANCES ACTIV-5/BET-B TRIAL EVALUATING LENZILUMAB
FROM A
PHASE 2 EXPLORATORY STUDY TO A PHASE 2/3 STUDY FOR THE TREATMENT
OF COVID-19
    * HUMANIGEN INC - ACTIV-5/BET-B TRIAL AMENDED IN CONTEXT OF
HUMANIGEN'S POSITIVE PHASE 3 LENZILUMAB LIVE-AIR STUDY
    * HUMANIGEN INC - APPROXIMATELY HALF OF 400 PATIENTS ARE
ALREADY
ENROLLED IN ACTIV-5/BET-B

Source text for Eikon:  ID:nBwbd2nZpa 
Further company coverage:  HGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))